Schizophrenia

Michael J Owen, Akira Sawa, Preben B Mortensen, Michael J Owen, Akira Sawa, Preben B Mortensen

Abstract

Schizophrenia is a complex, heterogeneous behavioural and cognitive syndrome that seems to originate from disruption of brain development caused by genetic or environmental factors, or both. Dysfunction of dopaminergic neurotransmission contributes to the genesis of psychotic symptoms, but evidence also points to a widespread and variable involvement of other brain areas and circuits. Disturbances of synaptic function might underlie abnormalities of neuronal connectivity that possibly involves interneurons, but the precise nature, location, and timing of these events are uncertain. At present, treatment mainly consists of antipsychotic drugs combined with psychological therapies, social support, and rehabilitation, but a pressing need for more effective treatments and delivery of services exists. Advances in genomics, epidemiology, and neuroscience have led to great progress in understanding the disorder, and the opportunities for further scientific breakthrough are numerous--but so are the challenges.

Copyright © 2016 Elsevier Ltd. All rights reserved.

Figures

Figure 1. The allelic spectrum of schizophrenia
Figure 1. The allelic spectrum of schizophrenia
The figure depicts risk alleles for schizophrenia that have been robustly identified by genomic studies. The x-axis is the allele frequency (AF) in controls and the the y-axis is the odds ratio (genotypic relative risk). For clarity, confidence intervals are not shown. Copy number variants associated with schizophrenia are shown as blue diamonds. Single nucleotide polymorphism that are associated with SCZ and are shown as red diamonds. Alleles that confer high individual risk are rare in the population due to the effects of natural selection, whereas those conferring small effects on individual risk can become common due to genetic drift or balancing selection.
Figure 2. Representative molecular pathway for schizophrenia:…
Figure 2. Representative molecular pathway for schizophrenia: fine tuning of the glutamate synapse
Recent advances in human genetics, from both GWAS and large-scale sequencing, have further supported the significance of fine-tuning of glutamatergic neurotransmission in the pathology of schizophrenia. The genes underscored by these studies include those encoding the glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A); glutamate receptor ionotropic, AMPA 1 (GRIA1); serine racemase (SRR); calcium channel, voltage-dependent (VDCC), L type, alpha 1C subunit; the ARC complex, and a number of proteins located in, or associated with, the postsynaptic density of glutamatergic synapses. The N-methyl D-aspartate (NMDA)-type glutamate receptors are fine tuned by a co-agonist D-serine, which is synthesized by SRR. The GRIN2A subunit (in dark green) dimerizes with other type of subunit, forming the NMDA receptors, whereas the GRIA1 subunit (in brown) also forms heterodimers for the AMPA receptors. VDCCs (e.g., the protein encoded by the CACNA1C gene) are also likely to be involved in tuning neural excitability and synaptic transmission via intracellular calcium signaling. Proteins associated with postsynaptic scaffold include PSD95, Stargazin, several kinases, Rho/Cdc42/Rac small G-proteins, and ARC complex. In response to activation of glutamate receptors, these proteins convey intracellular signaling that underlies cytoskeletal regulation and receptor trafficking crucial for synaptic plasticity.
Figure 3. Interaction of genetic and environmental…
Figure 3. Interaction of genetic and environmental risk factors in the developmental pathology of schizophrenia
This shows a schematic view of how multiple genetic and environmental risk factors might impact on long-term neurodevelopmental processes leading to schizophrenia. Schizophrenia typically presents when the first episode of psychosis occurs in late adolescence or early adulthood but is frequently preceded by a prodromal phase and in some instances premorbid impairments in cognition and/or social functioning go back many years. It is proposed that disturbances generated by susceptibility genes (indicated by blue stars) and environmental insults (indicated by pink asterisks) during early development and adolescence disturb postnatal brain maturation. These factors are likely to impair some of the crucial processes in early development, including progenitor cell proliferation, neuronal migration and dendritic arborization and outgrowth. Independent of such initial risks/insults, intrinsic disease-associated factors might also directly affect postnatal brain maturation. Accumulation of such deleterious insults results in overall disturbance of proper postnatal brain maturation, including maturation of interneurons and dopaminergic projections, pruning of glutamate synapses and myelination. Therefore, it is crucial to understand the mechanisms that underlie long-term progression to full disease manifestation in young adulthood to facilitate development of novel therapeutic strategies. This contrasts with classic drug discovery that simply modulates disturbed neurotransmission after full onset of the disease. In this figure, interneuron maturation is plotted as an increase in interneuron response to dopamine D2 agonists in the prefrontal cortex, whereas mesocortical dopaminergic projection is based on levels of tyrosine hydroxylase. The relative levels of glutamatergic synapse density and myelination are depicted. Extensively modified from the original figure appeared in Jaaro-Peled et al, TINS 2009.
Figure 4. Neuron-glia interactions in the cerebral…
Figure 4. Neuron-glia interactions in the cerebral cortex: key neural substrates for the pathology of schizophrenia
In the cerebral cortex, interneurons (inhibitory neurons) regulate the output of pyramidal neurons (excitatory neurons). Many studies have reported abnormalities of interneurons (in particular parvalbumin-positive interneurons) and deficits of dendritic spines in the pyramidal neurons in the pathology of schizophrenia. Imbalance of excitatory and inhibitory neurons may be a key feature that underlies the pathology. Recent neurobiology indicates that astrocytes and microglia play key a role in maintenance and pruning of the dendritic spines, in association with immune inflammatory response in the brain. Oligodendrocytes create the myelin sheath, which is crucial for signal transmission inside the axon. Abnormalities of these glial cells have also been reported in schizophrenia.

References

    1. Barbato A. Psychiatry in transition: outcomes of mental health policy shift in Italy. Aust N Z J Psychiatry. 1998;32(5):673–679.
    1. Kooyman I, Dean K, Harvey S, Walsh E. Outcomes of public concern in schizophrenia. Br J Psychiatry. 2007;194:s29–s36.
    1. Marwaha S, Johnson S. Schizophrenia and employment. Social Psychiatry and Psychiatric Epidemiology. 2004;39(5):337–349.
    1. Chesney E, Goodwin GM, Fazel S. Risks of all-cause and suicide mortality in mental disorders: a meta-review. World Psychiatry. 2014;13(2):153–160.
    1. Schizophrenia Commission. The abandoned illness: a report from the Schizophrenia Commission. London: Rethink Mental Illness. 2012
    1. Joyce EM, Roiser JP. Cognitive heterogeneity in schizophrenia. Curr Opin Psychiatry. 2007;20(3):268–272.
    1. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological psychiatry. 2001;50(11):884–897.
    1. Addington J, Heinssen R. Prediction and prevention of psychosis in youth at clinical high risk. Annu Rev Clin Psychol. 2012;8:269–289.
    1. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med. 2011;2:225–241.
    1. Association AP. Diagnostic and statistical manual of mental disorders : DSM-5. Fifth. Arlington, VA: American Psychiatric Association; 2013.
    1. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition: DSM-5. Arlington, VA: American Psychiatric Association; 2013.
    1. World Health Organisation. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation; 1992.
    1. Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going… but still not gone. Br J Psychiatry. 2010;196(2):92–95.
    1. Hyman SE. The diagnosis of mental disorders: the problem of reification. Annu Rev Clin Psychol. 2010;6:155–179.
    1. Owen MJ. New approaches to psychiatric diagnostic classification. Neuron. 2014;84(3):564–571.
    1. van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness–persistence–impairment model of psychotic disorder. Psychol Med. 2009;39(2):179–195.
    1. Craddock N, Owen MJ. Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry. 2007;6(2):84–91.
    1. van Os J, Kenis G, Rutten BPF. The environment and Schizophrenia. Nature. 2010;468:203–212.
    1. Gottesman II. A series of books in psychology. New York US: Freeman/Times Books/ Henry Holt & Co.; 1991. Schizophrenia genesis: The origins of madness.
    1. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a Complex Trait: Evidence From a Meta-analysis of Twin Studies. Arch Gen Psychiatry. 2003;60(12):1187–1192.
    1. Gottesman II, Shields J. A polygenic theory of schizophrenia. Proc Natl Acad Sci U S A. 1967;58(1):199–205.
    1. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet. 2012;13(8):537–551.
    1. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–427.
    1. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012;148(6):1223–1241.
    1. Rees E, Walters JT, Chambert KD, et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet. 2014;23(6):1669–1676.
    1. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Molecular psychiatry. 2012;17(2):142–153.
    1. Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nature genetics. 2008;40(7):880–885.
    1. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–184.
    1. Purcell SM, Moran JL, Fromer M, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–190.
    1. Bundy H, Stahl D, MacCabe JH. A systematic review and meta-analysis of the fertility of patients with schizophrenia and their unaffected relatives. Acta Psychiatrica Scandinavica. 2011;123(2):98–106.
    1. Rees E, Moskvina V, Owen MJ, O'Donovan MC, Kirov G. De Novo Rates and Selection of Schizophrenia-Associated Copy Number Variants. Biological Psychiatry. 2011;70(12):1109–1114.
    1. Cross-Disorder Group of the Psychiatric Genomics C. Lee SH, Ripke S, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature genetics. 2013;45(9):984–994.
    1. Hamshere ML, Stergiakouli E, Langley K, et al. Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry. 2013
    1. Kirov G, Rees E, Walters JTR, et al. The Penetrance of Copy Number Variations for Schizophrenia and Developmental Delay. Biological Psychiatry. 2014;75(5):378–385.
    1. Owen MJ. Implications of genetic findings for understanding schizophrenia. Schizophr Bull. 2012;38(5):904–907.
    1. Ruderfer DM, Fanous AH, Ripke S, et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2013
    1. Craddock N, Owen MJ. The Kraepelinian dichotomy – going, going… but still not gone. Br J Psychiatry. 2010;196:92–95.
    1. Grozeva D, Kirov G, Ivanov D, et al. Rare Copy Number Variants: A Point of Rarity in Genetic Risk for Bipolar Disorder and Schizophrenia. Arch Gen Psychiatry. 2010;67(4):318–327.
    1. Hall J, Trent S, Thomas KL, O’Donovan MC, Owen MJ. Genetic Risk for Schizophrenia: Convergence on Synaptic Pathways Involved in Plasticity. Biological Psychiatry. 2014
    1. Benros ME, Mortensen PB, Eaton W. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci. 2012;1262:56–66.
    1. Smyth AM, Lawrie SM. The Neuroimmunology of Schizophrenia. Clinical Psychopharmacology and Neuroscience. 2013;11(3):107–117.
    1. Baker K, Costain G, Fung WLA, Bassett AS. Chromosomal microarray analysis-a routine clinical genetic test for patients with schizophrenia. Lancet Psychiat. 2014;1(5):329–331.
    1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.
    1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635–645.
    1. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull. 2009;35(3):528–548.
    1. Khashan AS, Abel KM, McNamee R, et al. Higher risk of offspring schizophrenia following antenatal maternal exposure ot severe adverse life events. Arch Gen Psychiatry. 2008;65(2):146–152.
    1. Brown AS. Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism. Dev Neurobiol. 2012;72(10):1272–1276. Epub 2012 Aug 23.
    1. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med. 2013;43(2):239–257. Epub 2012 Apr 16.
    1. McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. ArchGenPsychiatry. 2010;67(9):889–894.
    1. Brown AS. The environment and susceptibility to schizophrenia. ProgNeurobiol. 2011;93(1):23–58.
    1. Cannon M, Kendell R, Susser E, Jones P. Prenatal and perinatal risk factors for schizophrenia. In: Murray RM, Jones PB, Susser E, Van Os J, Cannon M, editors. The epidemiology of schizophrenia. Cambridge: Cambridge University Press; 2003. pp. 74–99.
    1. Allardyce J, Boydell J. Review: the wider social environment and schizophrenia. Schizophr Bull. 2006;32(4):592–598. Epub 2006 Jul 18.
    1. Byrne M, Agerbo E, Eaton WW, Mortensen PB. Parental socio-economic status and risk of first admission with schizophrenia- a Danish national register based study. SocPsychiatry PsychiatrEpidemiol. 2004;39(2):87–96.
    1. Paksarian D, Eaton WW, Mortensen PB, Pedersen CB. Childhood Residential Mobility, Schizophrenia, and Bipolar Disorder: A Population-based Study in Denmark. Schizophr Bull. 2015;41(2):346–354. Epub 2014 Jun 5.
    1. Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38(4):661–671. Epub 2012 Mar 29.
    1. Cantor-Graae E, Pedersen CB. Full spectrum of psychiatric disorders related to foreign migration: a Danish population-based cohort study. JAMA Psychiatry. 2013;70(4):427–435.
    1. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry. 2005;162(1):12–24.
    1. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull. 2003;29(3):587–593.
    1. Vassos E, Pedersen CB, Murray RM, Collier DA, Lewis CM. Meta-analysis of the association of urbanicity with schizophrenia. Schizophr Bull. 2012;38(6):1118–1123. Epub 2012 Sep 26.
    1. McGrath JJ, Petersen L, Agerbo E, Mors O, Mortensen PB, Pedersen CB. A comprehensive assessment of parental age and psychiatric disorders. JAMA psychiatry (Chicago, Ill) 2014;71(3):301–309.
    1. Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull. 2011;37(5):1039–1047. Epub 2010 Feb 25.
    1. Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature. 2012;488(7412):471–475.
    1. Malaspina D, Harlap S, Fennig S, et al. Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry. 2001;58(4):361–367.
    1. Pedersen CB, McGrath J, Mortensen PB, Petersen L. The importance of father's age to schizophrenia risk. Molecular psychiatry. 2014;19(5):530–531.
    1. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319–328.
    1. Radhakrishnan R, Wilkinson ST, D'Souza DC. Gone to Pot - A Review of the Association between Cannabis and Psychosis. Front Psychiatry. 2014;5(54)
    1. Orlovska S, Pedersen MS, Benros ME, Mortensen PB, Agerbo E, Nordentoft M. Head injury as risk factor for psychiatric disorders: a nationwide register-based follow-up study of 113,906 persons with head injury. Am J Psychiatry. 2014;171(4):463–469.
    1. Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry. 2014;14(75):14–75.
    1. Benros ME, Eaton WW, Mortensen PB. The Epidemiologic Evidence Linking Autoimmune Diseases and Psychosis. Biological psychiatry. 2014;75:300–306.
    1. Muller N. Immunology of schizophrenia. Neuroimmunomodulation. 2014;21(2–3):109–116. Epub 2014 Feb 14.
    1. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia. A 30-year population-based register study. Am J Psychiatry. 2011;168(12):1303–1310.
    1. Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res. 2012;139(1–3):161–168. Epub Jun 15.
    1. Nielsen PFR, Benros ME, Mortensen PB. Hospital Contacts With Infection and Risk of Schizophrenia. A Population-Based Cohort Study With Linkage of Danish National Registers. 2014;40(6):1526–1532.
    1. Pasamanick B, Rogers ME, Lilienfeld AM. Pregnancy experience and the development of behavior disorders in children. Am J Psychiatry. 1956;112(8):613–618.
    1. Kirov G, Rees E, Walters JTR, et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biological psychiatry. 2014;75(5):378–385.
    1. Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. Nat Rev Neurol. 2014;10(11):643–660. Epub Oct 14.
    1. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. ProgNeurobiol. 2010;90(3):285–326.
    1. Giovanoli S, Engler H, Engler A, et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science. 2013;339(6123):1095–1099.
    1. Iyegbe C, Campbell D, Butler A, Ajnakina O, Sham P. The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. Soc Psychiatry Psychiatr Epidemiol. 2014;49(2):169–182. Epub 2014 Jan 17.
    1. Uher R. Gene-environment interactions in severe mental illness. Front Psychiatry. 2014;5(48)
    1. Borglum AD, Demontis D, Grove J, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci. Molecular psychiatry. 2014;19(3):325–333.
    1. Thomas D. Gene--environment-wide association studies: emerging approaches. NatRevGenet. 2010;11(4):259–272.
    1. Davey-Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.
    1. VanderWeele TJ, Vansteelandt S. Mediation Analysis with Multiple Mediators. Epidemiol Method. 2014;2(1):95–115.
    1. Agerbo E, Sullivan PF, Vilhjalmsson BJ, et al. Polygenic Risk Score, Parental Socioeconomic Status, Family History of Psychiatric Disorders and the Risk of Schizophrenia: A Danish Population-Based Study. JAMA Psychiatry. 2015 In press.
    1. Jarskog LF, Miyamoto S, Lieberman JA. Schizophrenia: new pathological insights and therapies. Annual review of medicine. 2007;58:49–61.
    1. Linden DE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73(1):8–22.
    1. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends in cognitive sciences. 2012;16(1):27–34.
    1. Lewis DA. Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions. The European journal of neuroscience. 2012;35(12):1871–1878.
    1. Meyer-Lindenberg A, Tost H. Neuroimaging and plasticity in schizophrenia. Restorative neurology and neuroscience. 2014;32(1):119–127.
    1. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull. 2013;39(5):1129–1138.
    1. Vita A, De Peri L, Deste G, Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Translational psychiatry. 2012;2:e190.
    1. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience and biobehavioral reviews. 2013;37(8):1680–1691.
    1. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677–1687.
    1. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain research bulletin. 2010;83(3–4):108–121.
    1. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2012;37(1):4–15.
    1. Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nature reviews Neuroscience. 2010;11(2):100–113.
    1. Ting JT, Peca J, Feng G. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annual review of neuroscience. 2012;35:49–71.
    1. Hall J, Trent S, Thomas KL, O'Donovan MC, Owen MJ. Genetic risk for schizophrenia: convergence on synaptic pathways involved in plasticity. Biological psychiatry. 2015;77(1):52–58.
    1. Ji K, Miyauchi J, Tsirka SE. Microglia: an active player in the regulation of synaptic activity. Neural plasticity. 2013;2013:627325.
    1. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333(6048):1456–1458.
    1. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron. 2012;74(4):691–705.
    1. Boulanger LM. Immune proteins in brain development and synaptic plasticity. Neuron. 2009;64(1):93–109.
    1. Boulanger LM, Shatz CJ. Immune signalling in neural development, synaptic plasticity and disease. Nature reviews Neuroscience. 2004;5(7):521–531.
    1. Fourgeaud L, Davenport CM, Tyler CM, Cheng TT, Spencer MB, Boulanger LM. MHC class I modulates NMDA receptor function and AMPA receptor trafficking. Proc Natl Acad Sci U S A. 2010;107(51):22278–22283.
    1. Huh GS, Boulanger LM, Du H, Riquelme PA, Brotz TM, Shatz CJ. Functional requirement for class I MHC in CNS development and plasticity. Science. 2000;290(5499):2155–2159.
    1. Lee H, Brott BK, Kirkby LA, et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature. 2014;509(7499):195–200.
    1. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annual review of neuroscience. 2012;35:369–389.
    1. Behrens MM, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318(5856):1645–1647.
    1. Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Current opinion in neurobiology. 2009;19(2):220–230.
    1. Cabungcal JH, Counotte DS, Lewis EM, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014;83(5):1073–1084.
    1. Sawa A, Seidman LJ. Is prophylactic psychiatry around the corner? combating adolescent oxidative stress for adult psychosis and schizophrenia. Neuron. 2014;83(5):991–993.
    1. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192(4238):481–483.
    1. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717–719.
    1. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 1989;99(Suppl):S18–S27.
    1. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
    1. Berrios GE. Positive and negative symptoms and Jackson. A conceptual history. Arch Gen Psychiatry. 1985;42(1):95–97.
    1. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–962.
    1. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annual review of medicine. 2013;64:393–406.
    1. Secher RG, Hjorthoj CR, Austin SF, et al. Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis. Schizophr Bull. 2015;41(3):617–626.
    1. Bentall RP. Madness explained: Psychosis and human nature. London: Penguin; 2003.
    1. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204(1):20–29.
    1. Goldsmith LP, Lewis SW, Dunn G, Bentall RP. Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variable analysis. Psychological medicine. 2015:1–9.
    1. Laursen TM, Nordentoft M, Mortensen PB. Excess Early Mortality in Schizophrenia. Annual Review of Clinical Psychology. 2014;10:425-.
    1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123–1131.
    1. Nordentoft M, Mortensen PB, Pedersen CB. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry. 2011;68(10):1058–1064.
    1. Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychological medicine. 2014;44(8):1625–1637.
    1. Poduri A, Evrony GD, Cai X, Walsh CA. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341(6141):1237758.
    1. Gamo NJ, Sawa A. Human stem cells and surrogate tissues for basic and translational study of mental disorders. Biological psychiatry. 2014;75(12):918–919.
    1. Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSC-derived neurons. Cell. 2011;145(6):831–834.
    1. Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: the new patient? Nature reviews Molecular cell biology. 2012;13(11):713–726.
    1. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–918.
    1. Steinberg EE, Christoffel DJ, Deisseroth K, Malenka RC. Illuminating circuitry relevant to psychiatric disorders with optogenetics. Current opinion in neurobiology. 2014;30C:9–16.
    1. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature. 2010;468(7321):203–212.
    1. Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular psychiatry. 2012;17(12):1206–1227.
    1. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Molecular psychiatry. 2011;16(3):321–332.
    1. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904–912.
    1. Field JR, Walker AG, Conn PJ. Targeting glutamate synapses in schizophrenia. Trends in molecular medicine. 2011;17(12):689–698.
    1. Harvey RJ, Yee BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nature reviews Drug discovery. 2013;12(11):866–885.
    1. Young JW, Geyer MA. Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochemical pharmacology. 2013;86(8):1122–1132.
    1. Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic) Br J Psychiatry. 2014;205(1):1–3.
    1. McCarroll SA, Hyman SE. Progress in the genetics of polygenic brain disorders: significant new challenges for neurobiology. Neuron. 2013;80(3):578–587.
    1. Heinssen RK, Insel TR. Preventing the onset of psychosis: not quite there yet. Schizophr Bull. 2015;41(1):28–89. Epub 2014 Nov 11.
    1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187–193.
    1. Uher R, Cumby J, MacKenzie LE, et al. A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry. 2014;14(1):344.
    1. Amminger GP, Schafer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–154.
    1. MQ. UK Mental health research funding. London: MQ; 2015.

Source: PubMed

3
Tilaa